<DOC>
	<DOCNO>NCT00975481</DOCNO>
	<brief_summary>Dimebon exhibit abuse potential compare placebo positive control ( alprazolam ) .</brief_summary>
	<brief_title>A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon ( Latrepirdine ) In Healthy Recreational Polydrug Users</brief_title>
	<detailed_description>The main purpose study determine whether dimebon exhibit abuse potential .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Huntington Disease</mesh_term>
	<mesh_term>Alprazolam</mesh_term>
	<criteria>Healthy male and/or female subject age 18 55 year . Recreational polydrug user history CNS depressant use . History clinically significant neurologic condition ( ) , seizures , convulsion , epilepsy , significant head injury , judge investigator designee . A known history hypersensitivity previous intolerance dimebon antihistamine . Selfreported history drug alcohol dependence ( except nicotine caffeine ) 2 year prior screen , drug alcohol dependence define ( DSMIVTR ) 12 month prior screen , include subject ever substance rehabilitation program ( treatment smoke cessation ) . History clinically significant psychiatric disorder ( ) , judge investigator qualify designee .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>oral single-dose 6-way crossover recreational drug user abuse potential pharmacodynamics safety</keyword>
</DOC>